Cortechs.ai | Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai grows quantitative brain imaging operations in Europe

(San Diego, CA) May 26, 2016 – Cortechs.ai, the leading medical software innovator providing trusted solutions for quantitative brain analysis, is pleased to announce the acceleration of its international expansion to the European market to address the growing demand for quantitative imaging solutions and to support its existing customer base in Europe.

Cortechs.ai’ flagship solution, NeuroQuant®, received CE mark clearance in 2014, paving the way for many European customers to use Cortechs.ai’ fully automated quantitative brain imaging solutions in clinical practice. Cortechs.ai’ quantitative imaging solutions, NeuroQuant and PETQuant™ provide neurologists, radiologists, and clinical researchers with accurate and convenient tools to quantify the volumes of specific brain structures providing evidenced-based assessments of brain atrophy which could be caused by neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

In conjunction with the expansion into Europe, Cortechs.ai has hired Peter Segers, MSc, to head the European team. Mr. Segers joins the company with over 18 years of market and business development experience in medical devices, with senior roles at Lightpoint Medical, Nucletron and BMEYE, as well as, Philips Medical Systems. He brings a wealth of expertise in building global enterprise relationships and has an extensive knowledge of medical imaging market. Mr. Segers is based out of Amsterdam.

“Our international expansion is a critical step in providing continuing access and support of Cortechs.ai’ proven and reliable quantitative volumetric analysis solutions,” said Guri Stark, CEO of Cortechs.ai. “NeuroQuant has experienced impressive acceptance and success in prominent clinical institutions in the US and we are excited to see the demand and growth in Europe as we expand our solutions and launch our new Multiple Sclerosis products later this summer.”

For more information about Cortechs.ai brain imaging analysis solutions, please visit Stand D40 at the 2nd Congress of the European Academy of Neurology (EAN) taking place May 28-31 in Copenhagen.

PETQuant is available for research use only.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis solutions provide neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

 

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

05/29/2025

Enhancing Imaging Workflow with DICOM SR: NeuroQuant®’s Seamless Integration 

As imaging becomes more data-driven, tools like NeuroQuant® with DICOM SR support pave the way for smarter, more connected radiology

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

05/13/2025

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

05/10/2025

All the Ways to Use the NeuroQuant Custom Report

With the ability to select structures from NeuroQuant’s 70+ structure parcellation atlas, the user has the power to truly personalize patient care!

05/04/2025

Introducing NeuroQuant MS Lesion Dynamics Computation: A Clearer Path to Understanding Disease Progression

Discover how the latest NeuroQuant MS update offers a clearer, more intuitive way to track lesion changes and understand disease progression over time.
Scroll to Top